Investing.com -- Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target citing a lack of near-term catalysts, the latter hacked it to $3 from $11.
Shares of Editas, the gene-editing company were down 23% at $1.45 on Friday.
Editas announced a strategic shift, ending its development of reni-cel and cutting its workforce by 65%. The company plans to focus entirely on in vivo therapeutic development, with clinical proof of concept at least two years away.
While Editas presented preclinical data supporting its in vivo approach for hematopoietic stem cells, Truist expressed concerns about competitive pressures and uncertainties surrounding the program.
Truist said it would stay on the sidelines due to limited value-creating opportunities within the next 12-18 months.
“Despite an evolving clinical profile that looks favorable, EDIT's decision to end development after extensive search did not yield a commercial partner is disappointing, and for us, pushes us to revisit our investment thesis in the stock,” Stifel analyst wrote.
Related Articles
Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%
Broadcom, Tesla lead Friday's market cap stock movers
Russia's Novatek working with lobbyists to thaw US relations, sources say
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。